The GNRH1 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from human 143B osteosarcoma cells. This product contains a targeted disruption of the GNRH1 gene, which encodes gonadotropin-releasing hormone 1, a critical neuropeptide governing reproductive function. The polyclonal format provides a heterogeneous loss-of-function model, allowing researchers to assess GNRH1-dependent phenotypes across a diverse pool of edited cells without the constraints of single-clone selection. This approach captures the inherent variability of CRISPR-mediated gene disruption and is particularly valuable for studying complex signaling networks in a cancer-relevant background.
The host cell line, 143B, is a well-established human osteosarcoma model originally derived from a malignant bone tumor biopsy. These cells are of mesenchymal origin and carry a mutation in the TP53 tumor suppressor gene, a common alteration in aggressive cancers. Widely utilized in cancer biology for investigations into tumor progression, metastasis, and therapeutic resistance, 143B cells offer a robust and genetically tractable system. Their rapid growth and compatibility with xenograft models make them an ideal platform for genetic ablation studies, and their p53 deficiency provides a context to explore cross-talk between tumor suppressor pathways and hormone-driven signaling.
GNRH1 functions as the master regulator of the hypothalamic-pituitary-gonadal axis by binding to its cognate receptor, GnRHR, a G??q/11-coupled GPCR. Ligand-receptor engagement activates phospholipase C, which generates second messengers IP3 and DAG, leading to intracellular calcium mobilization and protein kinase C activation. These events stimulate multiple mitogen-activated protein kinase cascades, including ERK, JNK, and p38, culminating in the transcriptional upregulation of gonadotropin genes FSHB and LHB. The signaling axis is modulated by upstream regulators such as KISS1, neurokinin B, dynorphin, and sex steroids (estrogen, progesterone), while interacting partners like ??-arrestin, calmodulin, and GPCR kinases fine-tune receptor desensitization and signal duration.
Embedded in the 143B osteosarcoma background, this GNRH1 knockout model enables dissection of the gene??s role in a malignant context. Although osteosarcomas do not typically express GNRH1, the model permits forced expression studies or evaluation of non-canonical GNRH1 activity when combined with exogenous ligands or receptor constructs. Moreover, because gonadotropins influence hormone-dependent cancers such as prostate, breast, and ovarian carcinomas, these knockout cells offer a unique system to investigate whether GNRH1 signaling intersects with oncogenic drivers altered by p53 loss and mesenchymal lineage programs.
These polyclonal knockout cells are tailored for a broad spectrum of research applications, including functional analysis of GnRH signaling through western blotting of phospho-ERK, -JNK, and -p38, and RT-qPCR profiling of FSHB and LHB expression. Calcium flux assays using fluorescent indicators permit real-time measurement of GnRHR-mediated responses, while reporter gene assays enable detailed mapping of transcriptional events downstream of GNRH1. ELISA-based detection of secreted gonadotropins and immunofluorescence staining further support mechanistic and screening studies. The model is particularly valuable for testing GnRH analogs and small-molecule modulators in hormone-dependent cancer and neuroendocrine research. For further information, please contact Ascent Research.
